1199 related articles for article (PubMed ID: 15191803)
21. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.
Baker KA; Hong M; Sadi D; Mendez I
Exp Neurol; 2000 Apr; 162(2):350-60. PubMed ID: 10739641
[TBL] [Abstract][Full Text] [Related]
22. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target grafting as a therapy for Parkinson's disease.
Collier TJ; Sortwell CE; Elsworth JD; Taylor JR; Roth RH; Sladek JR; Redmond DE
J Comp Neurol; 2002 Jan; 442(4):320-30. PubMed ID: 11793337
[TBL] [Abstract][Full Text] [Related]
23. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
[TBL] [Abstract][Full Text] [Related]
24. Environmental cue-dependent dopaminergic neuronal differentiation and functional effect of grafted neuroepithelial stem cells in parkinsonian brain.
Mine Y; Hayashi T; Yamada M; Okano H; Kawase T
Neurosurgery; 2009 Oct; 65(4):741-53; discussion 753. PubMed ID: 19834380
[TBL] [Abstract][Full Text] [Related]
25. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
26. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons.
González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M
J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855
[TBL] [Abstract][Full Text] [Related]
27. Human amniotic epithelial cells produce dopamine and survive after implantation into the striatum of a rat model of Parkinson's disease: a potential source of donor for transplantation therapy.
Kakishita K; Elwan MA; Nakao N; Itakura T; Sakuragawa N
Exp Neurol; 2000 Sep; 165(1):27-34. PubMed ID: 10964482
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models.
Kang UJ; Lee WY; Chang JW
Hum Cell; 2001 Mar; 14(1):39-48. PubMed ID: 11436352
[TBL] [Abstract][Full Text] [Related]
29. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
30. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Mar; 296(3):762-7. PubMed ID: 11181904
[TBL] [Abstract][Full Text] [Related]
31. [Expression of the enzymes of dopamine synthesis in non-dopaminergic neurons: functional significance and regulation].
Ugriumov MV
Usp Fiziol Nauk; 2007; 38(4):3-20. PubMed ID: 18064905
[TBL] [Abstract][Full Text] [Related]
32. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
[TBL] [Abstract][Full Text] [Related]
33. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
34. Influence of time in culture and BDNF pretreatment on survival and function of grafted embryonic rat ventral mesencephalon in the 6-OHDA rat model of Parkinson's disease.
Höglinger GU; Widmer HR; Spenger C; Meyer M; Seiler RW; Oertel WH; Sautter J
Exp Neurol; 2001 Jan; 167(1):148-57. PubMed ID: 11161602
[TBL] [Abstract][Full Text] [Related]
35. Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease.
Duan WM; Rodrigues CM; Zhao LR; Steer CJ; Low WC
Cell Transplant; 2002; 11(3):195-205. PubMed ID: 12075985
[TBL] [Abstract][Full Text] [Related]
36. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
37. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease.
Carvey PM; Ling ZD; Sortwell CE; Pitzer MR; McGuire SO; Storch A; Collier TJ
Exp Neurol; 2001 Sep; 171(1):98-108. PubMed ID: 11520124
[TBL] [Abstract][Full Text] [Related]
38. An in vitro interval before transplantation of mesencephalic reaggregates does not compromise survival or functionality.
Sortwell CE; Collier TJ; Camargo MD; Pitzer MR
Exp Neurol; 2004 May; 187(1):58-64. PubMed ID: 15081588
[TBL] [Abstract][Full Text] [Related]
39. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
[TBL] [Abstract][Full Text] [Related]
40. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
